Latest News in the pharma Industry

Research & Development

Major study confirms Novartis' Ultibro Breezhaler superiority over Seretide in preventing COPD exacerbations

Major study confirms Novartis' Ultibro Breezhaler superiority over Seretide in preventing COPD exacerbations

15 May 2016

Ultibro Breezhaler also significantly reduced the rate and prolonged the time to the first moderate or severe exacerbation, compared with Seretide.

Read more 
Veterinary medicine looking increasingly to human drugs to supplement treatment pipelines

Veterinary medicine looking increasingly to human drugs to supplement treatment pipelines

15 May 2016

Significant unmet needs within veterinary care are driving veterinarians to treat animals such as dogs, cats and horses by prescribing drugs intended for human use.

Read more 
BMS and AbbVie announce EC approval of Empliciti for the treatment of multiple myeloma in adults who have received at least one prior therapy

BMS and AbbVie announce EC approval of Empliciti for the treatment of multiple myeloma in adults who have received at least one prior therapy

12 May 2016

First and only immunostimulatory antibody approved in the European Union for multiple myeloma.

Read more 
LDC and Boehringer Ingelheim join forces to discover a novel approach for the treatment of schizophrenia

LDC and Boehringer Ingelheim join forces to discover a novel approach for the treatment of schizophrenia

11 May 2016

The novel approach builds on ground-breaking research results from Prof. Moritz Rossner and his team at the Max Planck Institute of Experimental Medicine in Göttingen.

Read more 
EC approves the first and only immuno-oncology combination, BMS's Opdivo + Yervoy Regimen, for treatment of advanced melanoma

EC approves the first and only immuno-oncology combination, BMS's Opdivo + Yervoy Regimen, for treatment of advanced melanoma

11 May 2016

Approval allows for the marketing of the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in all 28 Member States of the EU.

Read more 
Aptuit expands formulation capabilities through acquisition of Kuecept

Aptuit expands formulation capabilities through acquisition of Kuecept

10 May 2016

Expanding capabilities in formulation development to include specialist pre-formulation, formulation prototyping and formulation development services.

Read more 
FDA grants Priority Review for Lilly's olaratumab, an investigational medicine for advanced soft tissue sarcoma

FDA grants Priority Review for Lilly's olaratumab, an investigational medicine for advanced soft tissue sarcoma

8 May 2016

Lilly has received additional designations for olaratumab from the FDA, including Breakthrough Therapy, Fast Track and Orphan Drug, for this indication.

Read more 
Researchers find a way to deliver drugs to the placenta to support healthier pregnancies

Researchers find a way to deliver drugs to the placenta to support healthier pregnancies

8 May 2016

Discovery provides proof of principle for safe, targeted delivery of drugs to the placenta to improve pregnancy outcomes.

Read more 
Concert Pharmaceuticals unveils CTP-543 for treatment of alopecia areata

Concert Pharmaceuticals unveils CTP-543 for treatment of alopecia areata

5 May 2016

Phase I to Begin Second Quarter of 2016.

Read more 
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue

ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue

5 May 2016

Through this agreement, Sun Pharma commits development of Cissampelos pariera (Cipa), a botanical drug in collaboration with ICGEB.

Read more 
Graybug Vision announces $44.5 million Series B financing

Graybug Vision announces $44.5 million Series B financing

3 May 2016

The proceeds will be used to further the development of GB-102, Graybug Vision’s lead drug for wet AMD, through Phase II clinical trials and to initiate a clinical program for the company’s proprietary glaucoma compound.

Read more 
FDA approves ACADIA Pharmaceuticals’ Nuplazid (pimavanserin)

FDA approves ACADIA Pharmaceuticals’ Nuplazid (pimavanserin)

1 May 2016

The first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Read more